

# Technical Review Panel Member

## Curriculum Vitae

Name: Kristina Wallengren  
 Nationality: Swedish  
 Additional languages: English, Spanish, Swedish  
 Expertise: TB

### Qualifications

Qualification	Institution	Department	Year
MPH	Harvard School of Public Health, USA	International Health	2004
PhD	Karolinska Institute, Sweden	Cellular & Molecular Biology	2001
BS	Umeå University, Sweden	Molecular Biology	1991

### Employment History

Employer	Position	Place	Year
THINK International	Group CEO	Copenhagen, Denmark	2022 -
THINK TB & HIV Investigative Network	CEO	Durban, South Africa	2013-2021
K-RITH / AHRI	Clinical Advisor	Durban, South Africa	2010-2013
WHO	Technical Advisor	Durban, South Africa	2007-2008

Harvard University	Research Associate	Durban, South Africa	2005-2007
--------------------	--------------------	----------------------	-----------

## Relevant Publications

Staples S, Khan M. Howell, P; Juneja, S. Gupta, A; Programmatic introduction of BPaL regimen: A practical implementation guide (available in English and Russian) Stop TB; Nov. 2022; <https://www.stoptb.org/programmatic-introduction-of-bpal-regimen-practical-implementation-guide>

Hoddinott, G., Staples, S., Brown, R., Simwinga, M., Mubekapi Musadaidzwa, C., Hesselning, A., Hendricks, G., De Koker, P., MKenna, L. Community engagement for paediatric MDR-TB clinical trials; principles to support ethical trial implementation. International Journal of TB and Lung Disease. 22(5). S40-S45.

Von Groote-Bidlingmaier F., Patientia R., Sanchez E., Balanag Jr. V., Ticona E., Segura P., *et al.* Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respiratory Med 2019;7/3:249–59, doi:[http://dx.doi.org/10.1016/S2213-2600\(18\)30426-0](http://dx.doi.org/10.1016/S2213-2600(18)30426-0).

Moodliar, R. *et al.* Bedaquiline for multi-drug resistant TB, including extensively or pre-extensively drug-resistant pulmonary Mycobacterium tuberculosis, in adolescent patients. The International Journal of Tuberculosis and Lung Disease. 2018 (Nov) Volume 22 Number 11 Supplement 2 (Abstract OA 03-219-25 page S72)

Nunn, A.J. *et al.* A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis: N Engl J Med 2019; 380:1201-1213 DOI: 10.1056/NEJMoa1811867.

Pan, S.J., A. Tapley, J. Adamson, T. Little, M. Urbanowski, K. Cohen, A. Pym, D. Almeida, A. Dorasamy, E. Layre, D.C. Young, R. Singh, V.B. Patel, **K. Wallengren**, T. Ndung'u, D. Wilson, D.B. Moody, W. Bishai. Biomarkers for Tuberculosis Based on Secreted, Species-Specific, Bacterial Small Molecules. The Journal of Infectious Diseases. 2015 July 2. doi: 10.1093/infdis/jiv312

Loveday, M., **K. Wallengren**, J. Brust, J. Roberts, A. Voce, B. Margot, J. Ngozo, I. Master, G. Cassell, N. Padayatchi. Community-based care vs. centralised hospitalisation for MDR-TB patients KwaZulu-Natal, South Africa. Int. J. Tuberc. Lung Dis. 2015 Feb;19(2):163-71. doi: 10.5588/ijtld.14.0369. PubMed PMID: 25574914

Almeida D.V., S. Tyagi, S. Li, **K. Wallengren**, A.S. Pym, N.C. Ammerman, W.R. Bishai, J.H. Grosset. [Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice](#). Mycobact Dis. 2014 May 5;4:145. PubMed PMID: 25525563

Loveday M., N. Padayatchi, **K. Wallengren**, J. Roberts, J.C. Brust, J. Ngozo, I. Master, A. Voce. [Association between health systems performance and treatment outcomes in patients co-infected with MDR-TB and HIV in KwaZulu-Natal, South Africa: implications for TB programmes.](#) PLoS One. 2014 Apr 9;9(4):e94016. doi: 10.1371/journal.pone.0094016. eCollection 2014. PubMed PMID: 24718306

Loveday, M., N. Padayatchi, A. Voce, J. Brust, **K. Wallengren**. The treatment journey of a patient with multidrug-resistant tuberculosis in South Africa: is it patient-centred? *Int. J. Tuberc. Lung Dis.* 2013. 1 Oct;17(10 Suppl 1):56-9. doi: 10.5588/ijtld.13.0101. PubMed PMID: 24020603

Grosset J., D. Almeida, P.J. Converse, S. Tyagi, S.Y. Li, N.C. Ammerman, A.S. Pym, **K. Wallengren**, R. Hafner, U. Lalloo, S. Swindells, W.R. Bishai. Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. *Proc. Natl. Acad. Sci. U S A.* 2012 Sep 11;109(37):15001-5. doi: 10.1073/pnas.1203636109. Epub 2012 Aug 27. PubMed PMID: 22927424

Baker M.A., D. Wilson, **K. Wallengren**, A. Sandgren, O. Iartchouk, N. Broodie, S.D. Goonesekera, P.C. Sabeti, and M.B. Murray. Polymorphisms in the Gene That Encodes the Iron Transport Protein Ferroportin 1 Influence Susceptibility to Tuberculosis. *J. Infect. Dis.* 2012 Apr 1;205(7):1043-7. doi: 10.1093/infdis/jis026. Epub 2012 Feb 21. PubMed PMID: 22357659

Loveday M., **K. Wallengren**, A. Voce, B. Margot, T. Reddy, I. Master, J. Brust, K. Chaiyachati, N. Padayatchi. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. *Int. J. Tuberc. Lung Dis.* 2012 Feb;16(2):209-15. doi: 10.5588/ijtld.11.0401. PubMed PMID: 22236922

**Wallengren K.**, F. Scano, P. Nunn, B. Margot, S.S. Buthelezi, B. Williams, A. Pym, E. Y. Samuel, F. Mirzayev, W. Nkhoma, L. Mvusi, and Y. Pillay. Drug-Resistant Tuberculosis, KwaZulu-Natal, South Africa, 2001-2007. *Emerg. Infect. Dis.* 2011 Oct;17(10):1913-6. doi: 10.3201/eid1710.100952. PubMed PMID: 22000370

**Wallengren K.**, F. Scano, P. Nunn, B. Margot, S. Buthelezi, B. Williams, A. Pym, E. Y. Samuel, F. Mirzayev, W. Nkhoma, L. Mvusi, and Y. Pillay. Resistance to TB drugs in KwaZulu-Natal: causes and prospects for control. 2011 July 9. <http://arxiv.org/abs/1107.1800>

Cohen, T., D. Wilson, **K. Wallengren**, E.Y. Samuel, and M. Murray. Mixed-strain *Mycobacterium tuberculosis* infections among patients dying in a hospital in KwaZulu-Natal, South Africa. *J. Clin. Microbiol.* 2011 Jan;49(1):385-8. doi: 10.1128/JCM.01378-10. Epub 2010 Oct 27. PubMed PMID: 20980576.

Cohen, T., M. Murray, **K. Wallengren**, G.G. Alvarez, E.Y. Samuel, and D. Wilson. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in

KwaZulu-Natal, South Africa: A Postmortem study. PLoS Med. 2010 Jun 22;7(6):e1000296. doi: 10.1371/journal.pmed.1000296. PubMed PMID: 20582324

Schreiber, Y.S., A.F. Herrera, D. Wilson, **K. Wallengren**, R. Draper, J. Muller, H. Dawood, S. Doucette, D.W. Cameron and G.G. Alvarez. Tuberculosis retreatment category predicts resistance in hospitalised retreatment patients in a high HIV prevalence area. Int. J. Tuberc. Lung Dis. 2009 Oct;13(10):1274-80.